Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Debt (2020 - 2025)

Historic Total Debt for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to $30.4 million.

  • Eton Pharmaceuticals' Total Debt rose 63616.97% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 million, marking a year-over-year increase of 63616.97%. This contributed to the annual value of $29.8 million for FY2024, which is 45410.78% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Total Debt of $30.4 million as of Q3 2025, which was up 63616.97% from $30.2 million recorded in Q2 2025.
  • Eton Pharmaceuticals' Total Debt's 5-year high stood at $30.4 million during Q3 2025, with a 5-year trough of $364000.0 in Q2 2022.
  • Over the past 5 years, Eton Pharmaceuticals' median Total Debt value was $1.5 million (recorded in 2023), while the average stood at $7.0 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Total Debt tumbled by 5140.19% in 2022 and then surged by 63616.97% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Total Debt (Quarter) stood at $1.4 million in 2021, then decreased by 27.15% to $1.0 million in 2022, then soared by 420.81% to $5.4 million in 2023, then skyrocketed by 454.11% to $29.8 million in 2024, then rose by 1.87% to $30.4 million in 2025.
  • Its Total Debt was $30.4 million in Q3 2025, compared to $30.2 million in Q2 2025 and $29.8 million in Q4 2024.